-c-mudit-mathur-jpg
(c)Mudit Mathur
9 July 2015AsiaYuanqiong Hu

Under pressure: India’s progressive IP policies

India, with its progressive public health policies and patent laws, has long been known as the ‘pharmacy of the developing world’. With good reason: more than 96% of the antiretroviral medicines used to treat HIV purchased by donors for developing country treatment programmes are Indian-sourced generics. At Médecins Sans Frontières (MSF), we rely heavily on Indian generics to support the treatment of more than 200,000 people living with HIV/AIDS.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
27 May 2026   China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.
Asia
20 May 2026   Backed by the country’s wider AI ambitions, Google has signed a deal to roll out healthcare, scientific research, and safety initiatives.
Asia
31 March 2026   The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.